Innovative Kit Enhances Drug Discovery with Predictive Human Bioavailability Insights
[Cambridge, UK – November 2024] – CN Bio, a leading provider of Organ-on-a-Chip (OOC) systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability Assay Kit: Human 18. This new offering builds on the capabilities of the PhysioMimix® Multi-organ System, enabling improved lead optimization and preclinical testing processes. The kit provides a comprehensive, all-in-one solution for generating predictive insights into human oral bioavailability, facilitating better-informed decisions in lead candidate selection.
Enhancing Drug Development: The Role of Bioavailability in Preclinical Testing
Estimating bioavailability is a critical step in preclinical drug development, providing the essential data needed to determine safe and effective dosing in clinical trials. Traditionally, human drug bioavailability is estimated through a combination of in vitro assays, in vivo animal studies, and in silico modeling. However, each of these methods has limitations: in vitro models, such as 2D cell cultures, fail to fully replicate the complexity of drug absorption, while animal studies often suffer from significant physiological and metabolic differences that reduce the accuracy and translatability of the data.
A Novel Solution to Traditional Limitations
The PhysioMimix® Bioavailability Assay Kit: Human 18 was developed following the success of CN Bio’s PhysioMimix Bioavailability Assay introduced in January 2024 as part of the company’s ADME Contract Research Services. This development was in direct response to growing market demand for a new approach that addresses the shortcomings of traditional bioavailability estimation methods. The kit offers a streamlined, easy-to-use format that enables customers to quickly adopt and replicate the assay in their own laboratories.
Optimized for use with CN Bio’s PhysioMimix® Multi-organ System, the kit allows researchers to bridge the gap between in vitro and in vivo studies, delivering more accurate and reliable profiles of human oral drug bioavailability. This early-stage testing helps researchers select the most promising therapeutic candidates and design better-informed in vivo studies while minimizing the need for animal models.
Maximizing Clinical Success with Predictive In Vitro Data
Human bioavailability plays a pivotal role in selecting drug candidates for clinical trials, yet it remains an area poorly served by existing models. The PhysioMimix Bioavailability Assay Kit: Human 18 addresses this challenge by providing up to 18 replicates for researchers to profile their drug candidates in vitro. This approach minimizes risk and enhances the likelihood of clinical success by enabling more accurate predictions of bioavailability early in the development process. The kit also streamlines workflows, eliminating the need for complex assay development and validation, allowing researchers to rapidly implement Organ-on-a-Chip (OOC) technology.
Accelerating Drug Discovery with Industry-Leading Partnerships
“Recognizing the distinct market demand for new solutions to more accurately predict human bioavailability, we are pleased to be partnering with CN Bio to combine the benefits of our industry-leading single-organ models into a perfused and metabolically capable Gut/Liver-on-a-Chip model,” said Dr. Ben Scruggs, CEO of Altis Biosystems. “The Bioavailability Assay Kit: Human 18 allows users to harness the model’s capabilities directly in their own labs for the first time, providing a streamlined path to access predictive human data through an easy-to-use in vitro model.”
Dr. Yassen Abbas, Lead Scientist at CN Bio, added: “The PhysioMimix Bioavailability Assay Kit: Human 18 offers our customers a simple and effective solution for human bioavailability profiling. By providing up to 18 replicates, we’re enabling more robust data generation and reducing the uncertainty in early-stage drug development.”
Conclusion: A Key Tool for Drug Development Success
The launch of the PhysioMimix® Bioavailability Assay Kit: Human 18 represents a major step forward in improving the accuracy and efficiency of drug development workflows. With its ability to predict human bioavailability in a cost-effective, reproducible manner, the kit is poised to help researchers optimize their therapeutic candidates and accelerate the journey from bench to clinic.
Date:Nov 14 2024
Source:CN Bio
